Journal Article

The Sequence of Chemotherapy and Toripalimab Might Influence the Efficacy of Neoadjuvant Chemoimmunotherapy in Locally Advanced Esophageal Squamous Cell Cancer—A Phase II Study

Zheng, Yan, Xing, Wenqun, Ma, Baozhen, Li, Tiepeng, Wang, Zibing, Zhang, He, Liu, Liang, Zhao, Lingdi, Gao, Quanli, Shang, Yiman, Yuan, Dongfeng, Chai, Xiaofei, Fu, Xiaomin, Liu, Baoxing, Liang, Guanghui, Yang, Yonghao, Lin, Hongwei, Ren, Xiubao, Liu, Xianben, Qu, Jinrong, Zhang, Yong, Zhang, Jiangong

2021

Overview

There is no standard neoadjuvant therapy for locally advanced esophageal cancer in China. The role of neoadjuvant chemotherapy plus immunotherapy for locally advanced esophageal cancer is still being explored. This open-label, randomized phase II study was conducted at a single center between July 2019 and September 2020; 30 patients with locally advanced esophageal squamous cell carcinoma (ESCC) (T3, T4, or lymph-node positive) were enrolled. Patients were randomized according to the enrollment order at a 1:1 ratio to receive chemotherapy on day 1 and toripalimab on day 3 (experimental group) or chemotherapy and toripalimab on day 1 (control group). The chemotherapeutic regimen was paclitaxel and cisplatin. Surgery was performed 4 to 6 weeks after the second cycle of chemoimmunotherapy. The primary endpoint was pathological complete response (pCR) rate, and the secondary endpoint was safety and disease-free survival. Thirty patients completed at least one cycle of chemoimmunotherapy; 11 in the experimental group and 13 in the control group received surgery. R0 resection was performed in all these 24 patients. Four patients (36%) in the experimental group and one (7%) in the control group achieved pCR. The experimental group showed a statistically non-significant higher pCR rate ( = 0.079). PD-L1 combined positive score (CPS) examination was performed in 14 patients; one in the control group had a PD-L1 CPS of 10, and pCR was achieved; the remaining 13 all had ≤1, and 11 of the 13 patients received surgery in which two (in the experimental group) achieved pCR. Two patients endured ≥grade 3 adverse events, and one suffered from grade 3 immune-related enteritis after one cycle of chemoimmunotherapy and dropped off the study. Another patient died from severe pulmonary infection and troponin elevation after surgery. Although the primary endpoint was not met, the initial results of this study showed that delaying toripalimab to day 3 in chemoimmunotherapy might achieve a higher pCR rate than that on the same day, and further large-sample clinical trials are needed to verify this. ClinicalTrials.gov, identifier NCT03985670.

• Publisher: Frontiers Media SA,Frontiers Media S.A
• Subject: Aged / Antibodies / Antibodies, Monoclonal, Humanized - administration & dosage / Antibodies, Monoclonal, Humanized - adverse effects / Antineoplastic Agents - administration & dosage / Antineoplastic Agents - adverse effects / Cancer therapies / chemoimmunotherapy / Chemotherapy / Cisplatin / Cisplatin - administration & dosage / Cisplatin - adverse effects / Clinical trials / Drug Administration Schedule / Drug dosages / Endoscopy / Enrollments / Enteritis / Esophageal cancer / Esophageal carcinoma / Esophageal Neoplasms - diagnostic imaging / Esophageal Neoplasms - therapy / esophageal squamous cell carcinoma / Esophageal Squamous Cell Carcinoma - diagnostic imaging / Esophageal Squamous Cell Carcinoma - therapy / Esophagus / Female / Humans / Immunology / Immunotherapy / Immunotherapy - adverse effects / Lymphatic system / Lymphocytes / Magnetic Resonance Imaging / Male / Metastasis / Middle Aged / Neoadjuvant Therapy - adverse effects / Paclitaxel / Paclitaxel - administration & dosage / Paclitaxel - adverse effects / pathological complete response / Patients / PD-L1 protein / sequence / Squamous cell carcinoma / Statistical analysis / Surgery / toripalimab / Treatment Outcome / Troponin / Tumors / Ultrasonic imaging